Overview

Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropaties: a Cross-over Randomized Clinical Trial

Status:
Not yet recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to asses the serum uric-acid lowering effect of losartan in children with proteinuric nephropaties. Patients already treated with enalapril will be randomized to receive losartan or enalapril in a cross-over designed study. Those who recruit the inclusion criteria will receive enalapril and/or losartan during a one month period, followed by a 15 days of wash out (under enalapril treatment). On day 46, the second period of 30 days of treatment starts (enalapril or losartan, whichever was not received initially). Before randomization, a baseline 24 hours urine and a fasting blood sample will be obtained to asses uric acid excretion and serum uric acid values along with renal function and electrolyte levels. Then, similar determinations will be performed at days 30, 46 and 76.

Phase:

Phase 4

Details

Lead Sponsor:

Hospital General de Niños Pedro de Elizalde

Treatments:

Losartan